Opinion

Published within

« | ... | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | ... | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Yahoo!: advertising its downfall

Published By Datamonitor
08 Mar 2001
CommentWire
CommentWire

Yahoo!/HSBC: PayDirect from New York to Hong Kong

Published By Datamonitor
31 Jul 2001
ResearchWire
ResearchWire

xRM: CRM will continue to dominate the market

Published By Datamonitor
09 May 2002
Expert View
Expert View

Xolair: set for success?

The asthma treatment Xolair has moved a step closer to hitting the US market after an FDA advisory panel recommended it for approval. The decision represents a significant milestone for Xolair, which has been jointly developed by Genentech, Novartis and Tanox. The challenges facing Xolair look set to continue however, with the drug's success likely to be constrained by cost and safety issues.

Published By Datamonitor
16 May 2003
CommentWire
CommentWire

Xolair: breathing easy over FDA approval

Xolair, developed by Genentech, Novartis and Tanox, reduces the number of attacks in severe allergic asthmatics. However prescribing restrictions, safety concerns and high cost are expected to limit sales to $593 million by 2010. The drug's best chance of success is through label extensions for pediatric use and for allergic rhinitis.<BR />

Published By Datamonitor
19 May 2003
Expert View
Expert View

Xolair's proposed EU label may prove disappointing for Novartis

Novartis has received a positive opinion from a European committee recommending marketing authorization be granted to Xolair for severe persistent allergic asthma. Although Xolair has delivered impressive results, the restrictive label, together with high treatment costs, will limit its sales potential in the EU, meaning Novartis, and partner Genentech, may prefer to focus on the US market.

Published By Datamonitor
01 Aug 2005
CommentWire
CommentWire

XL: taking risks

XL Europe's $50 million capacity injection will place further strain on the already overstretched liability market and escalate fears that it is already starting to soften. XL's proven track record in liability business should enable it to win a substantial share of attractive risks and lessen its own exposure to an increasingly challenging market environment.

Published By Datamonitor
06 May 2005
Expert View
Expert View

Xigris: struggling to overcome its problems

The once lauded drug Xigris is struggling to recover from a series of setbacks, despite existing in a potentially lucrative market with little competition. After disappointing US sales, Xigris has now been launched in Europe. Datamonitor's Michael Randle asks if Eli Lilly can take advantage of its status as the only approved severe sepsis treatment and breathe new life into its sleeping giant.

Published By Datamonitor
15 Nov 2002
Expert View
Expert View

Xigris: Lilly's sepsis flop misses out

Eli Lilly's Xigris sales have proved disappointing, for the year-to-date period ending February 28 2002 sales reached just $14 million, bringing total sales to $35 million since the drug's launch in late November 2001. Industry analysts had predicted sales of between $300 and $500 million in 2002, but this now seems unrealistic, so where did it all go wrong?

Published By Datamonitor
22 Mar 2002
CommentWire
CommentWire

Xfera: going into hibernation

Published By Datamonitor
04 Oct 2001

« | ... | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | ... | » »|

No help is available.